$1.23
+0.00 (+0.00%)
Open$1.25
Previous Close$1.23
Day High$1.25
Day Low$1.20
52W High$8.50
52W Low$1.10
Volume—
Avg Volume51.9K
Market Cap4.95M
P/E Ratio—
EPS$-9.42
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,052.8% upside
Current
$1.23
$1.23
Target
$38.78
$38.78
$26.82
$38.78 avg
$44.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.63M | 2.53M | 2.93M |
| Net Income | 21.2K | 20.0K | 19.6K |
| Profit Margin | 0.8% | 0.8% | 0.7% |
| EBITDA | 30.9K | 30.5K | 37.6K |
| Free Cash Flow | 17.8K | 22.0K | 24.1K |
| Rev Growth | -5.2% | +23.9% | +20.0% |
| Debt/Equity | 0.27 | 0.26 | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |